Search Results for "hATTR"
Alnylam is committed to providing the healthcare community with balanced, accurate, and high-quality information about our science, therapeutic areas, and products.
More than one search term is recommended to yield the most relevant results. By searching, you confirm that your query is unsolicited.
For more information about our FDA-approved therapies, please see the Full Prescribing Information:
Vutrisiran: Survival and Mortality
Standard response letter on mortality and survival data from the HELIOS studies of vutrisiran.
Standard response letter on mortality and survival data from the HELIOS studies of vutrisiran.
Patisiran: APOLLO-B OLE Study
Standard response letter on the APOLLO-B OLE study of patisiran.
Standard response letter on the APOLLO-B OLE study of patisiran.
Patisiran: Use in Patients with hATTR Amyloidosis with Cardiomyopathy and Polyneuropathy
Standard response letter on the use of patisiran in patients with hATTR and mixed phenotype from the APOLLO-B study.
Standard response letter on the use of patisiran in patients with hATTR and mixed phenotype from the APOLLO-B study.
Givosiran: Hemin Use
Standard response letter on givosiran and hemin use. This medical information response contains clinical data from the ENVISION study.
Standard response letter on givosiran and hemin use. This medical information response contains clinical data from the ENVISION study.
